Skip to main content
Skip to "About government"
Language selection
English
Gouvernement du Canada /
Government of Canada
Recherche
Chercher dans le site Web
Recherche
Menu
Menu
principal
Emplois et milieu de travail
Immigration et citoyenneté
Voyage et tourisme
Entreprises et industrie
Prestations
Santé
Impôts
Environnement et ressources naturelles
Sécurité nationale et défense
Culture, histoire et sport
Services de police, justice et urgences
Transport et infrastructure
Canada et le monde
Argent et finances
Science et innovation
You are here:
Canada.ca
Bibliothèque et Archives Canada
Services
Services aux bibliothèques, archives et musées
Thèses Canada
Item – Thèses Canada
Contenu de la page
Item – Thèses Canada
Numéro d'OCLC
809971125
Lien(s) vers le texte intégral
Exemplaire de BAC
Exemplaire de BAC
Auteur
Pyra, Kim Alicia,1984-
Titre
Prebiotic fibre supplementation in combination with metformin modifies appetite, energy metabolism, and gut satiety hormones in obese rats.
Diplôme
M. Sc. -- University of Calgary, 2010
Éditeur
Ottawa : Library and Archives Canada = Bibliothèque et Archives Canada, [2011]
Description
2 microfiches
Notes
Includes bibliographical references.
Résumé
<?Pub Inc> The prebiotic fibre, oligofructose (OFS), reduces energy intake and improves glycemic control in rodents and man. Metformin (MT) is a commonly used insulin-sensitizing agent that may limit weight gain in individuals with type 2 diabetes. Our objective was to determine if using OFS as an adjunct to MT therapy (AD) modifies satiety hormone production and metabolism in obese rats. Independently, OFS and MT decreased energy intake, body fat, hepatic triglyceride content, plasma leptin and glucose-dependent insulinotropic peptide (GIP) levels. OFS and AD but not MT rats showed superior glycemic control during an oral glucose tolerance test (OGTT) compared to C. Area under the curve for GIP was lowest in ADThe prebiotic fibre, oligofructose (OFS), reduces energy intake and improves glycemic control in rodents and man. Metformin (MT) is a commonly used insulin-sensitizing agent that may limit weight gain in individuals with type 2 diabetes. Our objective was to determine if using OFS as an adjunct to MT therapy (AD) modifies satiety hormone production and metabolism in obese rats. Independently, OFS and MT decreased energy intake, body fat, hepatic triglyceride content, plasma leptin and glucose-dependent insulinotropic peptide (GIP) levels. OFS and AD but not MT rats showed superior glycemic control during an oral glucose tolerance test (OGTT) compared to C. Area under the curve for GIP was lowest in AD.
ISBN
9780494696002
0494696001
Date de modification :
2022-09-01